Akademik Veri Yönetim Sistemi
10th International Dermatology And Cosmetology Congress (Indercos), İstanbul, Türkiye, 17 - 20 Nisan 2025, cilt.1, ss.189-192, (Tam Metin Bildiri)
INTRODUCTION&OBJECTIVES: Cutaneous metastasis (CM) occurs through direct, hematogenous, lymphatic spread, or iatrogenic implantation of primary tumour (PT) cells into the skin. CM, which accounts for 2% of all skin cancers, is reported in 0.6% to 10.4% of cancer patients. Although CM generally indicates advanced-stage cancer, early diagnosis is imperative given that it can represent the initial indication of cancer in 0.8% to 24% of cases. This study aimed to evaluate the demographic, clinical, histopathological characteristics, and survival outcomes of patients with CM at our tertiary care hospital. MATERIALS&METHODS: All histopathologically confirmed CM cases diagnosed in our clinic between January 2009 and March 2025 were included in our single-centre retrospective observational study. RESULTS: A total of 99 patients with CM were included, 47.47% (N=47) of whom were men. The mean age at diagnosis was 61.43 years (range: 35– 97). The most common PT sites were breast (32.32%; N=32) and lung (24.24%; N=24). All patients had advanced-stage cancer. CM commonly affected the chest (31.37%, N=32) and the back/buttocks (13.72%, N=14). CM presented as nodules (47.47%; N=47), tumours (32.32%; N=32), plaques (13.13%; N=13), ulcerations (2.02%, N=2), erysipeliod (1.01%, N=1) and disfigurement (1.01%, N=1). Histologically, ductal carcinoma was the most common (31.31%, N=31), followed by adenocarcinoma (28.28%, N=28). Positron emission tomography/computed tomography (PET/ CT) detected skin involvement in 19 patients (19.19%) before CM diagnosis. CM was the first sign of cancer in 7.07% (N=7) of patients. The occurrence of CM was categorized as early (7.07%, N=7), synchronous 190 (14.14%, N=14), and metachronous (74.74%, N=74). The mean interval between PT and CM diagnosis was 37 (0-300) months. The mean follow-up time until death (77.77%; N=77) was 16.51 (0-156) months and the mean follow-up time for surviving patients (22.22%; N=22) was 41.04 (2-180) months. The treatments included chemotherapy (48.48%; N=48), combination chemotherapy and radiotherapy (15.15%; N=15), and radiotherapy (9.9%; N=9). CONCLUSION: CMs are rare and may be the first indication of malignancy or recurrence. In our study, the most common PTs were breast and lung cancer. PET/CT detected skin involvement in only 19 of 99 patients before CM diagnosis, suggesting that its utility in identifying CM is limited. In the literature, the mean follow-up time until death ranges from 5 to 9.4 months, whereas for surviving patients, this period is reported to be between 18.4 and 20 months. In our study, these values were determined as 16.51 months and 41.04 months, respectively. These differences may be attributed to racial and ethnic factors, as well as the accessibility of oncological treatments. Despite this results, CM continues to be indicative of a poor prognosis. Therefore, clinicians should emphasize the early diagnosis of suspicious skin lesions to improve survival outcomes